The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of ...

Based on the Phase II data, Imbria Pharmaceuticals’ inerafaxstat could complement existing treatments rather than replace them.

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic ...

Completed biopharma IPOs that raised more than $100 million saw a twofold increase during the year. Biopharmaceutical initial ...

For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy ...

Ensuring the highest standards in pharmaceutical logistics is crucial for patient safety and treatment efficacy.

Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.